PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34790046-0	2021	Long noncoding RNA CEBPA-DT promotes cisplatin chemo-resistance through CEBPA/BCL2 mediated apoptosis in oral squamous cellular cancer.	Cisplatin	37-46	CCAAT enhancer binding protein alpha	Homo sapiens	72-77	
34790046-4	2021	Here, we found that the expression of lncRNA CEBPA-DT/CEBPA/BCL2 was upregulated in cisplatin resistance OSCC cells (Cal27-CisR and HSC4-CisR) compared with their parental cells (Cal27 and HSC4).	Cisplatin	84-93	CCAAT enhancer binding protein alpha	Homo sapiens	54-59	
34790046-6	2021	Down-regulation of CEBPA-DT enhances cisplatin sensitivity, facilitates cell apoptosis in cisplatin-resistant OSCC cells.	Cisplatin	37-46	CCAAT enhancer binding protein alpha	Homo sapiens	19-24	
34790046-6	2021	Down-regulation of CEBPA-DT enhances cisplatin sensitivity, facilitates cell apoptosis in cisplatin-resistant OSCC cells.	Cisplatin	90-99	CCAAT enhancer binding protein alpha	Homo sapiens	19-24	
34790046-7	2021	In addition, we identified that CEBPA-DT regulates cisplatin chemosensitivity through CEBPA/BCL2-mediated cell apoptosis.	Cisplatin	51-60	CCAAT enhancer binding protein alpha	Homo sapiens	32-37	
34790046-7	2021	In addition, we identified that CEBPA-DT regulates cisplatin chemosensitivity through CEBPA/BCL2-mediated cell apoptosis.	Cisplatin	51-60	CCAAT enhancer binding protein alpha	Homo sapiens	86-91	
34790046-8	2021	Knockdown of CEBPA and BCL2 could alleviate the increasement of cisplatin resistance induced by CEBPA-DT overexpression.	Cisplatin	64-73	CCAAT enhancer binding protein alpha	Homo sapiens	13-18	
34790046-9	2021	Our findings indicate that downregulation of lncRNA CEBPA-DT may be a potential therapy to overcome cisplatin resistance in OSCC.	Cisplatin	100-109	CCAAT enhancer binding protein alpha	Homo sapiens	52-57